Roth Capital Has Weak Forecast for REVB FY2028 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Equities research analysts at Roth Capital lowered their FY2028 earnings estimates for Revelation Biosciences in a research report issued to clients and investors on Thursday, June 5th. Roth Capital analyst J. Aschoff now expects that the company will earn $0.84 per share for the year, down from their prior forecast of $1.00. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($49.33) per share.

Separately, Wall Street Zen cut shares of Revelation Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd.

Revelation Biosciences Price Performance

REVB stock opened at $0.87 on Monday. Revelation Biosciences has a 52-week low of $0.77 and a 52-week high of $60.80. The company has a 50-day moving average of $2.62 and a two-hundred day moving average of $4.52. The stock has a market capitalization of $833,860.00, a price-to-earnings ratio of 0.00 and a beta of -0.09.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings results on Thursday, May 8th. The company reported ($2.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.88) by $4.77.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.